Ignite Creation Date:
2025-12-25 @ 4:19 AM
Ignite Modification Date:
2026-01-21 @ 10:24 PM
Study NCT ID:
NCT05283720
Status:
RECRUITING
Last Update Posted:
2025-12-18
First Post:
2022-03-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma
Sponsor:
Genmab
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Non-Hodgkin Lymphoma | View |
Keywords:
Keywords
| Keyword Brief | Keyword Text | View |
|---|---|---|
| None | Non-Hodgkin Lymphoma | View |
| None | Epcoritamab | View |
| None | Lenalidomide | View |
| None | Ibrutinib | View |
| None | Polatuzumab Vedotin | View |
| None | Rituximab | View |
| None | Cyclophosphamide | View |
| None | Doxorubicin Hydrochloride (HCl] | View |
| None | Prednisone (pola-R-CHP) | View |
| None | ABBV-GMAB-3013 | View |
| None | Cancer | View |
| None | Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL), Venetoclax, | View |
| None | Venclexta | View |
| None | ABT-199 | View |
| None | GDC-0199 | View |
| None | CC-99282 | View |
| None | EPCORE | View |
| None | Pirtobrutinib | View |
| None | Mantle Cell Lymhoma | View |